Quarterly report · Q1
4544.TEDINET S100RLNC
Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥56.6bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥260.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥65.3bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | −¥1.7bn | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥8.6bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | −¥1.5bn | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥22.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.5bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥1.2bn | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥8.1bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.1bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥15.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.6bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.1bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥5.6bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥289.6bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥297.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥278.3bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥139.8bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥147.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥149.8bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥150.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥146.0bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥32.7bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥44.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥32.7bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥44.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥39.7bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥6.2bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥32.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.0bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥29.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.3bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.7bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.4bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-19.67 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥275.52 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥98.25 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥275.5 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥98.24 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 51.7% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.4% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | −¥1.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | −¥1.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥1.6bn |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥36.1bn |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥36.1bn |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥18m |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥2.8bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥14.7bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥13.4bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥1.4bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥2.3bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥7.2bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥7.2bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥1m |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥355m |
| —segment total | revenue | 2023-04-01 → 2023-06-30 | ¥58.0bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥56.6bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥1.4bn |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | −¥121m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥3.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥3.5bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥607m |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥43.4bn |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥43.4bn |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥27m |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥1.7bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥18.5bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥15.0bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3.5bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥7.0bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥7.0bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥7.0bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥4m |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥440m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥68.8bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥65.3bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3.5bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥9.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 459
| Item | Context | Value | Unit |
|---|---|---|---|
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | － | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | 3500000000 | JPY |
| Repayments of finance lease obligations fin cf | Prior1YTDDuration | -1052000000 | JPY |
| Repayments of finance lease obligations fin cf | CurrentYTDDuration | -1086000000 | JPY |
| Other net fin cf | Prior1YTDDuration | 0 | JPY |
| Other net fin cf | CurrentYTDDuration | 398000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | -6442000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -1671000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 887000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 371000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -6752000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -11450000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 46479000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 44185000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 39727000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 32735000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 43358000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 14978000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q1r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 6994000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 65331000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 65331000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 27000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 3476000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q1r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 4000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 3509000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -3509000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 43386000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 18455000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q1r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 6999000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 68840000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -3509000000 | JPY |
| Net sales | Prior1YTDDuration | 65331000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 1712000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 7034000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q1r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 440000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 9187000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -607000000 | JPY |
| Operating income | Prior1YTDDuration | 8580000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 36097000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 13360000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q1r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 7162000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 56620000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 56620000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E00967-000ClinicalLabTestingBusinessReportableSegmentsMember | 18000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E00967-000InVitroDiagnosticsBusinessReportableSegmentsMember | 1367000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q1r_E00967-000SterilizationAndRelatedServicesReportableSegmentsMember | 1000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 1387000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |